NCT00557492View on ClinicalTrials.gov

Efficacy of Neoadjuvant Chemoradiation for Potentially Resectable Pancreas Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

March 31, 2012

Study Completion Date

December 31, 2016

Conditions
Pancreatic Cancer
Interventions
DRUG

Avastin (bevacizumab)

10 mg/kg, days 1, 15, 29 and 43

DRUG

Gemzar (Gemcitabine)

On days 1, 15, and 29, subjects will receive gemcitabine 1500 mg/m2 IV over 150 minutes at the fixed-dose rate (10 mg/m2/min).

RADIATION

external beam radiotherapy

3 Gy/fraction utilizing a 95% isodose field over 10 consecutive weekdays, Monday to Friday, for a total of 30 Gy

Trial Locations (1)

15232

University of Pittsburgh Medical Centers, Pittsburgh

All Listed Sponsors
lead

Amer Zureikat

OTHER

NCT00557492 - Efficacy of Neoadjuvant Chemoradiation for Potentially Resectable Pancreas Cancer | Biotech Hunter | Biotech Hunter